WO2001034185A3 - Induction of mucosal immunity by vaccination via the skin route - Google Patents

Induction of mucosal immunity by vaccination via the skin route Download PDF

Info

Publication number
WO2001034185A3
WO2001034185A3 PCT/US2000/030897 US0030897W WO0134185A3 WO 2001034185 A3 WO2001034185 A3 WO 2001034185A3 US 0030897 W US0030897 W US 0030897W WO 0134185 A3 WO0134185 A3 WO 0134185A3
Authority
WO
WIPO (PCT)
Prior art keywords
induction
mucosal immunity
vaccination via
skin route
methods
Prior art date
Application number
PCT/US2000/030897
Other languages
French (fr)
Other versions
WO2001034185A2 (en
Inventor
Dexiang Chen
Sangeeta Bhargava
Deborah Fuller
Original Assignee
Powderject Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Vaccines Inc filed Critical Powderject Vaccines Inc
Priority to JP2001536182A priority Critical patent/JP2003528818A/en
Priority to CA002390999A priority patent/CA2390999A1/en
Priority to AU14814/01A priority patent/AU784781B2/en
Priority to IL14945800A priority patent/IL149458A0/en
Priority to EP00977135A priority patent/EP1229932A2/en
Priority to NZ518765A priority patent/NZ518765A/en
Publication of WO2001034185A2 publication Critical patent/WO2001034185A2/en
Publication of WO2001034185A3 publication Critical patent/WO2001034185A3/en
Priority to IL149458A priority patent/IL149458A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Methods for generating an immune response at a mucosal surface are described. Compositions suitable for use in the methods for generating an immune response at a mucosal surface are also described. In addition, methods for treating or preventing a disease caused by the entry of a pathogen into the body of a subject via a mucosal surface are provided.
PCT/US2000/030897 1999-11-10 2000-11-09 Induction of mucosal immunity by vaccination via the skin route WO2001034185A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2001536182A JP2003528818A (en) 1999-11-10 2000-11-09 Induction of mucosal immunity by vaccination via the skin route
CA002390999A CA2390999A1 (en) 1999-11-10 2000-11-09 Induction of mucosal immunity by vaccination via the skin route
AU14814/01A AU784781B2 (en) 1999-11-10 2000-11-09 Induction of mucosal immunity by vaccination via the skin route
IL14945800A IL149458A0 (en) 1999-11-10 2000-11-09 Induction of mucosal immunity by vaccination via the skin route
EP00977135A EP1229932A2 (en) 1999-11-10 2000-11-09 Induction of mucosal immunity by vaccination via the skin route
NZ518765A NZ518765A (en) 1999-11-10 2000-11-09 Induction of mucosal immunity by vaccination via the skin route
IL149458A IL149458A (en) 1999-11-10 2002-05-02 Transdermal vaccine composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43769199A 1999-11-10 1999-11-10
US09/437,691 1999-11-10

Publications (2)

Publication Number Publication Date
WO2001034185A2 WO2001034185A2 (en) 2001-05-17
WO2001034185A3 true WO2001034185A3 (en) 2001-11-22

Family

ID=23737480

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030897 WO2001034185A2 (en) 1999-11-10 2000-11-09 Induction of mucosal immunity by vaccination via the skin route

Country Status (8)

Country Link
EP (1) EP1229932A2 (en)
JP (1) JP2003528818A (en)
CN (1) CN100340290C (en)
AU (1) AU784781B2 (en)
CA (1) CA2390999A1 (en)
IL (2) IL149458A0 (en)
NZ (1) NZ518765A (en)
WO (1) WO2001034185A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911742B2 (en) 1996-11-14 2014-12-16 The United States Of America As Represented By The Secretary Of The Army Transcutaneous immunization without heterologous adjuvant

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002252378B2 (en) 2001-03-19 2007-10-18 Intercell Usa, Inc. Transcutaneous immunostimulation
EP1425423B1 (en) 2001-08-13 2010-06-23 University of Rochester Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
GB0218921D0 (en) * 2002-08-14 2002-09-25 Glaxosmithkline Biolog Sa Novel vaccine
WO2004028561A1 (en) * 2002-09-30 2004-04-08 Yamanouchi Pharmaceutical Co., Ltd. Method of inducing immune responses
DE102004057007B4 (en) 2003-12-23 2020-03-19 BSH Hausgeräte GmbH Household appliance with programmable control module
WO2006060710A2 (en) * 2004-12-02 2006-06-08 Becton, Dickinson And Company Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
CN114401739A (en) * 2019-09-03 2022-04-26 电化株式会社 Seasonal influenza vaccine capable of inducing virus specific antibody in nasal cavity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027961A1 (en) * 1997-12-02 1999-06-10 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19729492A1 (en) * 1997-07-10 1999-02-11 Forschungszentrum Juelich Gmbh Method and device for serial sampling

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027961A1 (en) * 1997-12-02 1999-06-10 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BABIUK S ET AL: "Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery", JOURNAL OF CONTROLLED RELEASE,NL,ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, vol. 66, no. 2-3, May 2000 (2000-05-01), pages 199 - 214, XP004193068, ISSN: 0168-3659 *
GLENN ET AL: "Advances in vaccine delivery: transcutaneous immunisation", EXPERT OPINION ON INVESTIGATIONAL DRUGS,GB,ASHLEY PUBLICATIONS LTD., LONDON, vol. 8, no. 6, June 1999 (1999-06-01), pages 797 - 805, XP002110056, ISSN: 1354-3784 *
MOLDOVEANU Z ET AL: "CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus", VACCINE,GB,BUTTERWORTH SCIENTIFIC. GUILDFORD, vol. 16, no. 11-12, 1 July 1998 (1998-07-01), pages 1216 - 1224, XP004124627, ISSN: 0264-410X *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911742B2 (en) 1996-11-14 2014-12-16 The United States Of America As Represented By The Secretary Of The Army Transcutaneous immunization without heterologous adjuvant

Also Published As

Publication number Publication date
CN1414861A (en) 2003-04-30
AU1481401A (en) 2001-06-06
NZ518765A (en) 2005-07-29
CN100340290C (en) 2007-10-03
IL149458A (en) 2008-08-07
IL149458A0 (en) 2002-11-10
AU784781B2 (en) 2006-06-15
WO2001034185A2 (en) 2001-05-17
JP2003528818A (en) 2003-09-30
EP1229932A2 (en) 2002-08-14
CA2390999A1 (en) 2001-05-17

Similar Documents

Publication Publication Date Title
HK1043731A1 (en) Vaccine against antigens from bacteriae
HK1037125A1 (en) Methods and products for inducing mucosal immunity
PL351893A1 (en) Vaccines
SI1031346T1 (en) Noninvasive vaccination through the skin
MY113428A (en) Hepatitis b vaccine
IL158107A0 (en) Human papillomaviruses vaccine
HK1039895A1 (en) Immunogenic complexes and methods relating thereto
NO20001768L (en) Virus encapsulation vaccine, method of preparation and use thereof
WO2000018351A3 (en) Aglyco products and methods of use
WO2001068129A3 (en) Adjuvant for vaccines
WO2002036790A3 (en) Influenza virus vector for infection of dendritic cells
WO2001034185A3 (en) Induction of mucosal immunity by vaccination via the skin route
NO20024255D0 (en) HIV Immune Adjuvant Therapy
ZA200200731B (en) Novel strategy for carbohydrate-based therapeutic vaccines.
FR2715304B1 (en) Anti-allergic vaccine.
MXPA01010701A (en) Vaccine.
WO2002070004A3 (en) Papillomavirus vaccines
MXPA03004454A (en) Imidazolone derivatives for the treatment of viral diseases.
ZA997265B (en) Leptospira vaccine antigens for the prevention of leptospirosis.
HK1041606A1 (en) Process for the preparation of n,n'-carbonylbislactams.
AU2001278407A1 (en) Device for treating immune diseases
ZA200000142B (en) Adjuvants for use in vaccines.
AU3085800A (en) Restorative and regenerative preparation, method for producing the same and therapeutical use according to l.v. dubinina
EG23398A (en) Evaluation of the immunizing pontential of pseudomonas aeuruginosa vaccine in chickens.
ITMI20030034A1 (en) MACHINE FOR THE PREPARATION OF COFFEE OR ANALOGUE BEVERAGES.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 149458

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 518765

Country of ref document: NZ

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 536182

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2390999

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000977135

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 14814/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 008181594

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2000977135

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 518765

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 518765

Country of ref document: NZ